Share chart Cyclo Therapeutics, Inc.
Extended chart
Simple chart
About Cyclo Therapeutics, Inc.
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of neurodegenerative diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo that is in Phase IIb clinical trials for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. more details| IPO date | 2011-02-23 |
|---|---|
| ISIN | US23254X2018 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://cyclotherapeutics.com |
| Цена ао | 0.7206 |
| Change price per day: | 0% (0.7206) |
|---|---|
| Change price per week: | +2.94% (0.7) |
| Change price per month: | -6.29% (0.769) |
| Change price per 3 month: | +20.5% (0.598) |
| Change price per half year: | -8.67% (0.789) |
| Change price per year: | -48.16% (1.39) |
| Change price per 3 year: | -74.72% (2.85) |
| Change price per 5 year: | +325.13% (0.1695) |
| Change price per year to date: | +21.07% (0.5952) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Founders Fund V Management, LLC | 480708 | 1.67 |
| Vanguard Group Inc | 355223 | 1.24 |
| Geode Capital Management, LLC | 152077 | 0.53 |
| Founders Fund VI Management, LLC | 110023 | 0.38 |
| Citadel Advisors Llc | 54018 | 0.19 |
| Blackrock Inc. | 48444 | 0.17 |
| State Street Corporation | 39525 | 0.14 |
| Wealth Enhancement Advisory Services, LLC | 18513 | 0.06 |
| Northern Trust Corporation | 17453 | 0.06 |
| XTX Topco Ltd | 10696 | 0.04 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| iShares Micro-Cap ETF | 0.00344 | 17.09 | 1.54048 |
| 0 | 17.09 | 1.54 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. N. Scott Fine | CEO & Director | 569.92k | 1957 (68 years) |
| Mr. C. E Strattan | Founder & Director | N/A | 1946 (79 years) |
| Mr. Joshua M. Fine | CFO & Secretary | 421.17k | 1982 (43 years) |
| Mr. Michael Eric Lisjak | Senior VP of Business Development & Chief Regulatory Officer | 430.4k | 1974 (51 year) |
| Dr. Jeffrey L. Tate Ph.D. | COO, Chief Quality Officer & Director | 255.14k | 1958 (67 years) |
| Dr. Karen Mullen FFPM | Interim Chief Medical Officer | N/A | |
| Ms. Lori McKenna | Global Head of Patient Advocacy | N/A |
Address: United States, Gainesville. FL, 6714 NW 16th Street - open in Google maps, open in Yandex maps
Website: https://cyclotherapeutics.com
Website: https://cyclotherapeutics.com
